Pacific Biosciences of California PACB, popularly known as PacBio and Form Bio, a provider of advanced computational life sciences technology, recently collaborated and announced a range of new initiatives intended toward advancing and unifying the Adeno-associated virus (AAV) industry. The initiatives, including an AAV data dictionary, open-source tools and more, are being driven by a new AAV Working Group, jointly assembled by Form Bio and PacBio and composed of leading AAV experts across industry and academia. More on the Collaboration Owing to its non-pathogenic characteristics, AAV is acknowledged as one of the most promising methods in gene therapy. Yet, industry silos that result in different languages and approaches, which can vary significantly amongst other companies and institutions operating at the forefront of AAV innovation, often impede cooperation on AAV-based initiatives. Additionally, top specialists are gathered by Form Bio and PacBio to create the AAV Working Group, which is tasked with developing and advancing standardized reporting guidelines and nomenclature to support consistency and dependability in AAV research and development. More on PacBio’s Existing Technologies PacBio is a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and resolve genetically complex problems. The company’s products and technology under development stem from two highly differentiated core technologies, which include HiFi long-read sequencing technology and Sequencing by Binding(SBB) short-read sequencing technology. PacBio has developed HiFi long-read sequencing based on SMRT technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. The company is also expanding its genomic solutions with its short-read SBB chemistry, which offers sensitive sequencing for short-read applications. Upon the launch of the SBB platform, PacBio believes it will be the only company offering both native long-read and native short-read technologies into the market. In March, PacBio announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with severe neurological disorders. In February, the company announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system —the HiFi Prep Kit 96 and the HiFi Plex Prep Kit 96. In January, PacBio announced PanDNA, a versatile Nanobind DNA extraction kit designed to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types, including cells, bacteria, blood, tissue, plant nuclei and insects. Industry Prospects Per a report by Grand View Research, the global long-read sequencing market size was valued at $455.1 million in 2022 and is expected to witness a growth rate of 30.92% from 2023 to 2030. The major factors driving the market growth include the rising prevalence of genetic diseases, such as cancers, as well as chromosomal disorders, the increasing popularity of personalized medicine, and rising technological advancements resulting in the emergence of newer technologies, such as third-generation sequencing. Notable Developments In March 2024, PacBio announced the PureTarget repeat expansion panel, a new approach that makes it possible to thoroughly examine 20 genes linked to severe neurological conditions, including difficult-to-sequence genes with tandem repeat expansions, is now possible. In January 2024, PacBio announced PanDNA, a versatile Nanobind DNA extraction kit. With the addition of this new offering, the range of sample types appropriate for long-read sequencing is now greater and includes bacteria, cells, tissue, blood, plant nuclei, and insects. Price Performance For the past six months, PACB’s shares have plunged 86% against the industry’s rise of 5.8%. The S&P 500 increased 15.1% in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider PACB carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, Ecolab ECL and Universal Health Services UHS. DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 44% compared with the industry’s 20.4% rise in the past year. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year. Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank #2 at present. UHS has an estimated earnings growth rate of 30.5% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
PacBio (PACB) and Form Bio to Boost AAV Industry Development
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...